John Bridgeman
Chief Scientific Officer Immunokey
Seminars
Thursday 26th February 2026
CARKey: a CAR-T Platform to Mitigate Tumour Antigen Heterogeneity & On-Target-off Tumour Toxicity
1:30 pm
- Development of CARKey platform technology with multireceptor targeting
- Identification of combinatorial target proteins through bioinformatic analysis
- Rapid and strategic development of clinical candidate
New Data
